Issue 30, 2021

GSH-resistant and highly cytoselective ruthenium(ii)-p-cymene-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents

Abstract

To avoid the side effects of the current popular platinum-based anticancer drugs, researchers have made tireless attempts to design appropriate GSH-resistant Ru(II)-arene complexes. In this regard, luminescent ruthenium(II)-p-cymene-imidazophenanthroline complexes were developed as promising highly cytoselective cancer theraputic agents for HeLa and Caco-2 cells.

Graphical abstract: GSH-resistant and highly cytoselective ruthenium(ii)-p-cymene-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents

Supplementary files

Article information

Article type
Communication
Submitted
18 May 2021
Accepted
12 Jul 2021
First published
12 Jul 2021

Dalton Trans., 2021,50, 10369-10373

GSH-resistant and highly cytoselective ruthenium(II)-p-cymene-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents

B. Kar, U. Das, S. De, S. Pete, A. Sharma S, N. Roy, A. K. S. K., D. Panda and P. Paira, Dalton Trans., 2021, 50, 10369 DOI: 10.1039/D1DT01604K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements